Alembic Pharma to launch 25 drugs in US generic segment in FY25

17 May 2024 , 12:00 PM

Alembic Pharmaceuticals’ top executive stated that the company is preparing for a busy launch schedule in the US market in fiscal year 25.

Pranav Amin, MD of Alembic Pharma, stated “We are planning to introduce 25 new products in the US generic segment FY25.”

“We have EIRs (establishment inspection reports) for all of our facilities, so there is no regulatory overhang,” Amin stated. Alembic Pharma’s revenue in FY24 increased by 19% YoY to ₹6,229 Crore, with 28% coming from the US business. The India business, which accounts for 35%, rose by 7% in FY24.

Alembic plans to invest ₹550-₹600 Crore on R&D in FY25, focusing on creating a pipeline of medicines for the US market, including injectables, ophthalmology, cancer, inhalation, and dermatological. Amin said that capital expenditures will be low for the next two years, with the focus on debottlenecking existing plants.

The Vadodara-based drugmaker, which has been around for nearly a century, is a late entrant into the US market. It has more than made up for that. The company has been investing heavily in R&D, spending between ₹700-₹750 Crore annually to develop products for the US market. Additionally, it has invested over ₹1,800 Crore in three new USFDA-compliant manufacturing facilities.

Alembic Pharma’s India business has had moderate growth due to decreasing antibiotic offtake.

“Every year, we will introduce 20-25 new products, including line extensions. We will continue to do so as fresh releases fuel India’s 2.5%-3% growth,” said RK Baheti, director of finance.

At around 11.52 AM, Alembic Pharma was trading marginally higher at ₹970.40, against the previous close of ₹970 on NSE. The counter touched an intraday high and low of ₹980.95, and ₹962.85, respectively.

For feedback and suggestions, write to us at [e-mail]

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/